INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.…
INmune Bio (INMB) Q3 2026 Earnings Call Transcript
INmune Bio (NASDAQ: INMB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 21 employees.
The shares were at 0.8270 USD on 20 November 2026, down 49.3% over 52 weeks. Its 52-week range is 0.8189 USD to 2.600 USD, and it trades at the bottom of that range.
Its market capitalisation is 25.60M USD.
INmune Bio reports return on equity of -195.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 15.12M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 29 March 2027.